SCHEMBL6479480

SCHEMBL6479480

CC[Si](CC)(CC)O[C@H](CI)c1ccc(OCc2ccccc2)c(NS(C)(=O)=O)c1

nearest known ligand 0.44

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
CYP19A1 P11511 4/20 0.44
TRPV1 Q8NER1 3/20 0.42
ADRB3 P13945 6/20 0.41
NPC1 O15118 1/20 0.40
AR P10275 1/20 0.40
HPGD P15428 1/20 0.40
RAB9A P51151 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
PDE4A P27815 1/20 0.39
PDE4B Q07343 1/20 0.39
PDE4C Q08493 1/20 0.39
PDE4D Q08499 1/20 0.39
ESRRA P11474 1/20 0.39
F2 P00734 1/20 0.38
F10 P00742 1/20 0.38
PRSS1 P07477 1/20 0.38
F7 P08709 1/20 0.38
PTPN1 P18031 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5483348 1.00 CYP19A1 (0.44) CYP19A1TRPV1ADRB3NPC1AR
SCHEMBL4817546 1.00 CYP19A1 (0.44) CYP19A1TRPV1ADRB3NPC1AR
SCHEMBL7605348 0.90 CYP19A1 (0.44) CYP19A1TRPV1ADRB3NPC1AR
SCHEMBL7605339 0.90 CYP19A1 (0.44) CYP19A1TRPV1ADRB3NPC1AR
SCHEMBL7109194 0.89 AR (0.43) CYP19A1TRPV1ADRB3NPC1AR
SCHEMBL7111557 0.89 AR (0.43) CYP19A1TRPV1ADRB3NPC1AR
SCHEMBL7109191 0.89 AR (0.43) CYP19A1TRPV1ADRB3NPC1AR
SCHEMBL6986483 0.87 ADRB3 (0.48) CYP19A1TRPV1ADRB3PDE4APDE4B
SCHEMBL8817465 0.86 CYP19A1 (0.43) CYP19A1TRPV1ADRB3NPC1AR
SCHEMBL9234212 0.84 CYP19A1 (0.46) CYP19A1TRPV1ADRB3NPC1AR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050043358-A1 Aminoalcohol derivatives and their use as beta 3 adrenergic agonists FUJISAWA PHARMACEUTICAL CO. LTD. (JP) 2005-02-24 US disclosed
US-20020143034-A1 Aminoalcohol derivatives and their use as beta 3 adrenergic agonists FUJISAWA PHARMACEUTICAL CO. LTD. (JP) 2002-10-03 US disclosed
EP-1140849-A1 AMINOALCOHOL DERIVATIVES AND THEIR USE AS BETA 3 ADRENERGIC AGONISTS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2001-10-10 EP disclosed
WO-2000040560-A1 AMINOALCOHOL DERIVATIVES AND THEIR USE AS BETA 3 ADRENERGIC AGONISTS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2000-07-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020143034-A1 Aminoalcohol derivatives and their use as beta 3 adrenergic agonists ADRB1, ADRB2, ADRB3 CYP19A1 2541/4885TRPV1 1235/4885ADRB3 3/4885
US-20050043358-A1 Aminoalcohol derivatives and their use as beta 3 adrenergic agonists ADRB2, ADRB1, ADRB3 CYP19A1 2410/4885TRPV1 991/4885ADRB3 3/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.